Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
Quality of Generic Drugs Manufactured Overseas Comes into Question
The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...
Who Foots the Surprise Bill?
As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...
More Than 40 States File Suit Against Generic Drug Manufacturers
Forty-three states and Puerto Rico have filed a lawsuit against 20 of the largest U.S. generic drug manufacturers. They allege that the companies manipulated...
Benchmarking Drug Prices Could Save the U.S. Billions on Medicare Part D
The U.S. could save billions by pegging drug prices to what other countries pay, according to a new study in Health Affairs.
The research indicates...
Coming Soon to a TV Near You: List Prices for Drugs
Television advertisements for prescription drugs will soon need to include list prices, according to new regulations from the U.S. Department of Health and Human...
Current Issue
May 2019, Volume 5, Issue 6
This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.
